Johnson & Johnson (NYSE: JNJ) stocks moved forwardTuesday on the release of fourth-quarter and full-year 2021 results.
The health-care behemoth out of New Brunswick, New Jersey reported full-year sales were $93.8 Billion reflecting growth of 13.6%, operational sales growth of 12.2%, and adjusted operational sales growth of 12.8%.
2021 Fourth-Quarter EPS of $1.77 increased 172.3%; adjusted EPS of $2.13 increased 14.5%
2021 Full-Year EPS of $7.81 increased 41.7%; adjusted EPS of $9.80 increased 22.0%.
JNJ’s guidance calls for 2022 adjusted operational sales growth of 7.7%* and adjusted operational EPS growth of 9.2%.
"Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers" said CEO Joaquin Duato.
"Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond."
Consumer Health worldwide adjusted operational sales increased 3.8% primarily driven by over-the-counter (OTC) products including TYLENOL analgesics and digestive health, in addition to NEUTROGENA and AVEENO products in Skin Health / Beauty primarily due to COVID-19 market recovery.
Pharmaceutical worldwide adjusted operational sales grew 13.6% driven in part by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma.
JNJ shares gathered $1.23 to $64.20.
